Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.45 |
| ▸ | LSS | P48449 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | HRH2 | P25021 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7118163 | 0.89 | F10 (0.44) | F10LSS | |
| SCHEMBL6576136 | 0.84 | CYP3A4 (0.47) | F10LSS | |
| SCHEMBL7115221 | 0.77 | MAPT (0.43) | F10LSSRORCHRH1HRH3 | |
| SCHEMBL5632390 | 0.75 | ALDH1A1 (0.45) | F10HRH1HRH3HRH2 | |
| SCHEMBL6578432 | 0.75 | F10 (0.46) | F10LSS | |
| SCHEMBL7119668 | 0.74 | F10 (0.42) | F10LSS | |
| SCHEMBL5632401 | 0.72 | F10 (0.55) | F10HRH1HRH3HRH2 | |
| SCHEMBL7119420 | 0.72 | MAPT (0.45) | F10RORCHRH1HRH3 | |
| SCHEMBL9761106 | 0.71 | SIGMAR1 (0.64) | F10HRH3 | |
| SCHEMBL9759900 | 0.71 | ADRB1 (0.52) | F10HRH1HRH3HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2003-11-06 | — | — | US | claimed |
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207882-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | F2, SERPINC1, F11 | F10 8/4885LSS 608/4885RORC 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.